These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 31734038)

  • 1. Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease.
    Agin-Liebes J; Cortes E; Vonsattel JP; Marder K; Alcalay RN
    Parkinsonism Relat Disord; 2020 May; 74():76-77. PubMed ID: 31734038
    [No Abstract]   [Full Text] [Related]  

  • 2. Authors' replies to the comments of Koga et al. on "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease".
    Hickman RA; Vonsattel JP; Agin-Liebes J; Marder K; Alcalay RN
    Parkinsonism Relat Disord; 2020 Oct; 79():131-132. PubMed ID: 32928644
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the editor, "Movement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's disease".
    Koga S; Dickson DW; Wszolek ZK
    Parkinsonism Relat Disord; 2020 Oct; 79():130. PubMed ID: 32921567
    [No Abstract]   [Full Text] [Related]  

  • 4. Lack of central and peripheral nervous system synuclein pathology in R1441G
    Vilas D; Gelpi E; Aldecoa I; Grau O; Rodriguez-Diehl R; Jaumà S; Martí MJ; Tolosa E
    J Neurol Neurosurg Psychiatry; 2019 Jul; 90(7):832-833. PubMed ID: 30054313
    [No Abstract]   [Full Text] [Related]  

  • 5. Enteric alpha-synuclein pathology in LRRK2-G2019S Parkinson's disease.
    Rouaud T; Clairembault T; Coron E; Neunlist M; Anheim M; Derkinderen P
    Parkinsonism Relat Disord; 2017 Jul; 40():83-84. PubMed ID: 28483388
    [No Abstract]   [Full Text] [Related]  

  • 6. Misfolded α-Synuclein Seeding Is Detected in Suspected LRRK2-Parkinson's Disease without Immunohistochemically Detectable α-Synuclein Pathology.
    Kim A; Martinez-Valbuena I; Keith JL; Kovacs GG; Lang AE
    Mov Disord; 2024 Jan; 39(1):218-220. PubMed ID: 37986700
    [No Abstract]   [Full Text] [Related]  

  • 7. A novel rare variant of LRRK2 associated with familial Parkinson's disease: p.R1501W.
    Masuzugawa S; Nishioka K; Imai Y; Ogata J; Shojima Y; Li Y; Yoshino H; Hattori N
    Parkinsonism Relat Disord; 2020 Jul; 76():46-48. PubMed ID: 32563051
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduced LRRK2 in association with retromer dysfunction in post-mortem brain tissue from LRRK2 mutation carriers.
    Zhao Y; Perera G; Takahashi-Fujigasaki J; Mash DC; Vonsattel JPG; Uchino A; Hasegawa K; Jeremy Nichols R; Holton JL; Murayama S; Dzamko N; Halliday GM
    Brain; 2018 Feb; 141(2):486-495. PubMed ID: 29253086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 pathobiology in Parkinson's disease - virtual inclusion.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2016 Oct; 139 Suppl 1():75-76. PubMed ID: 26899799
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of LRRK2 and α-Synuclein in Parkinson's Disease.
    Daher JP
    Adv Neurobiol; 2017; 14():209-226. PubMed ID: 28353286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LRRK2 kinase inhibitors reduce alpha-synuclein in human neuronal cell lines with the G2019S mutation.
    Zhao Y; Keshiya S; Perera G; Schramko L; Halliday GM; Dzamko N
    Neurobiol Dis; 2020 Oct; 144():105049. PubMed ID: 32800998
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathological Functions of LRRK2 in Parkinson's Disease.
    Jeong GR; Lee BD
    Cells; 2020 Nov; 9(12):. PubMed ID: 33266247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert comment: "A case of missing pathology in a patient with LRRK2 Parkinson's disease".
    Kalia LV
    Parkinsonism Relat Disord; 2020 May; 74():78-79. PubMed ID: 31727562
    [No Abstract]   [Full Text] [Related]  

  • 14. LRRK2 G2019S Mutation Inhibits Degradation of α-Synuclein in an In Vitro Model of Parkinson's Disease.
    Hu D; Niu JY; Xiong J; Nie SK; Zeng F; Zhang ZH
    Curr Med Sci; 2018 Dec; 38(6):1012-1017. PubMed ID: 30536063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease.
    Arora S; Visanji NP; Mestre TA; Tsanas A; AlDakheel A; Connolly BS; Gasca-Salas C; Kern DS; Jain J; Slow EJ; Faust-Socher A; Lang AE; Little MA; Marras C
    J Parkinsons Dis; 2018; 8(4):503-510. PubMed ID: 30248062
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathophysiological heterogeneity in Parkinson's disease: Neurophysiological insights from LRRK2 mutations.
    Kojovic M; Kassavetis P; Pareés I; Georgiev D; Rocchi L; Balint B; Foltynie T; Rothwell J; Bhatia K
    Mov Disord; 2017 Sep; 32(9):1333-1335. PubMed ID: 28686318
    [No Abstract]   [Full Text] [Related]  

  • 17. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leucine-rich repeat kinase 2 and alternative splicing in Parkinson's disease.
    Elliott DA; Kim WS; Gorissen S; Halliday GM; Kwok JB
    Mov Disord; 2012 Jul; 27(8):1004-11. PubMed ID: 22528366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRRK2-associated Parkinson's disease patients have better stereopsis than idiopathic Parkinson disease.
    Sun L; Chan P
    Clin Neurol Neurosurg; 2018 Jun; 169():174-177. PubMed ID: 29705653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Modeling of Leucine-Rich Repeat Kinase 2 G2019S-Mediated Parkinson's Disease Pathology.
    Vermilyea SC; Emborg ME
    Stem Cells Dev; 2018 Jul; 27(14):960-967. PubMed ID: 29402177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.